研究单位：[1]Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China, 430030[2]Wuhan Union Hospital, China[3]Renmin Hospital of Wuhan University[4]Wuhan University[5]Hubei Cancer Hospital
研究目的：
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.
